Calls for papers
-
Bloomberg has published an article about GSK’s overhaul of its R&D organization that describes former head of the allergic inflammation discovery performance unit Roberto Solari as “one of the casualties of the company’s new approach… Read more . . .
-
AstraZeneca has asked the New Zealand High Court to review a decision by Pharmac, the government drug purchasing agency, to reduce its subsidy for the Symbicort Turbuhaler to achieve pricing parity with GSK’s Seretide (Advair)… Read more . . .
-
The Michael J. Fox Foundation (MJFF) for Parkinson’s Research (MJFF) has awarded a grant to Civitas Therapeutics to support development of the company’s lead product, CVT-301, an inhaled levodopa (L-dopa) formulation for the treatment of… Read more . . .
-
Shortly after announcing a co-promotion deal with Eisai for its inhaled COPD drugs in Japan, Novartis has filed a new drug application in that country for one of those drugs, NVA237 inhaled glycopyrronium bromide, according… Read more . . .
-
According to a study published in the November 24 issue of the New England Journal of Medicine, intermittent administration of a high dose of inhaled budesonide resulted in no more exacerbations over the course of… Read more . . .
-
The New York Microscopical Society has recognized Malvern Instruments Chief Technology Officer E. Neil Lewis with its Ernst Abbe Memorial Award for outstanding contributions to the science of microscopy. The society specifically cited Dr. Lewis’s… Read more . . .
-
The approximately 800 million inhalers sold annually worldwide generate approximately 10,000 tons of waste, estimates Graham Purkins of Novartis, a member of the the Device Working Group of IPAC-RS. In response to growing concern from… Read more . . .
-
Tokyo-based Eisai will co-promote three Novartis inhaled COPD therapies in Japan with Novartis Pharma K.K. Starting on December 1, 2011, both companies will promote Onbrez indacaterol inhalation capsules, with Novartis targeting flagship and university hospitals… Read more . . .
-
According to the Hong Kong Department of Health (DH), Nycomed (Hong Kong) has voluntarily recalled a batch of Omnaris ciclesonide nasal spray due “a quality defect.” The product, from batch number 137930, was manufactured in… Read more . . .
-
Two Phase 3 studies to evaluate the safety of twice daily doses of a fixed dose combination dry powder formulation of aclidinium bromide and formoterol fumarate in 3,500 patients with moderate to severe COPD have… Read more . . .
Featured event:
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
July 13-July 16: 2026 ISAM Congress, Taipei, Taiwan
September 15-September 18: DDL New Researcher Network Summer Event, London, UK
September 16-September 17: IPAC-RS 2026 Nasal Innovation Forum, Jersey City, NJ, USA
September 24-September 25: Inhaled & Nasal Biologics | DNA Forum, Cambridge, UK